| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Pyott David E I, Director
Received 3,780 shares by exercise or conversion ($272K) |
| 12 Nov 2026 | Form 4 |
| 12 Nov 2026 |
Form 4: Schulman Amy W, Director
Bought 1,910 shares ($300K) |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 30 Oct 2026 | SCHEDULE 13G |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) – |
| 06 Oct 2026 |
Form 4: Supran Bryan, EVP, CLO and Secretary
Sold 1,758 shares ($399K) |
| 02 Oct 2026 | 144 |
| 22 Sep 2026 |
Form 4: Greenstreet Yvonne, Director
Received 107 shares as a grant or award |
| 30 Jul 2026 | 10-Q |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) – |
| 03 Jun 2026 |
Form 4: Pyott David E I, Director
Received 3,830 shares by exercise or conversion · Sold 3,830 shares ($1.15M) |
| 03 Jun 2026 |
Form 4: Cravatt Benjamin, Director
Granted 4,393 Stock Option (Right to Buy) |
| 03 Jun 2026 |
Form 3: Cravatt Benjamin, Director
No securities owned |
| 01 Jun 2026 | 144 |
Loading...